EGFR and ovarian cancer: Amplifications, mutations, and overexpression of EGFR family members have been described in epithelial ovarian cancer, and pre-clinical data have suggested that interfering with the signalling activity of these pathways in ovarian cancer cells can result in antitumour activity.